Distinguishing hepatic hemangiomas from metastatic tumors using T1 mapping on gadoxetic-acid-enhanced MRI

Magn Reson Imaging. 2013 Jan;31(1):23-7. doi: 10.1016/j.mri.2012.06.026. Epub 2012 Aug 9.

Abstract

Objective: The objective was to evaluate the usefulness of T1 mapping in distinguishing hepatic hemangiomas from metastatic tumors on gadoxetic-acid-enhanced magnetic resonance imaging.

Methods: We examined 20 hemangiomas in 14 patients and 21 metastatic tumors in 11 patients. We performed T1 mapping using the double-flip angle method before and after the injection of gadoxetic acid. Quantitative evaluation was carried out using the pre- and post-contrast enhancement ratios (CERs), and qualitative evaluation was conducted to evaluate the added value of T1 mapping using receiver operating characteristics analysis.

Results: The mean CERs of metastatic tumors at 70 s, 240 s and 20 min after the injection of gadoxetic acid were 1.54 (95% confidence interval: 1.37-1.71), 1.47 (1.34-1.6) and 1.30 (1.19-1.41); those of hemangiomas were 3.36 (2.41-4.31), 3.06 (2.44-3.68) and 2.20 (2.02-2.38), respectively. The mean CERs of hemangiomas were significantly higher than those of metastatic tumors (P<.05). When the mean CER cutoff value 20 min after the injection was set at 1.6, the diagnostic sensitivity of hepatic hemangiomas was 100%. There was no added value observed statistically in the qualitative evaluation of T1 mapping (P>.05).

Conclusion: It is valuable to evaluate quantitatively T1 mapping 20 min after hepatobiliary phase acquisition in the case of difficulty in distinguishing hepatic hemangiomas from metastatic tumors qualitatively.

MeSH terms

  • Adult
  • Aged
  • Contrast Media
  • Diagnosis, Differential
  • Female
  • Gadolinium DTPA*
  • Humans
  • Image Enhancement / methods
  • Liver Neoplasms / pathology*
  • Liver Neoplasms / secondary*
  • Magnetic Resonance Imaging / methods*
  • Male
  • Middle Aged
  • Reproducibility of Results
  • Sensitivity and Specificity

Substances

  • Contrast Media
  • gadolinium ethoxybenzyl DTPA
  • Gadolinium DTPA